The Distribution of Free and Non-Ionic Vesicular Sodium Stibogluconate in the Dog

被引:16
作者
Collins, Michelle [1 ]
Carter, K. Christine [2 ]
Baillie, Alan J. [1 ]
O'Grady, John [2 ]
机构
[1] Univ Strathclyde, Dept Pharmaceut Sci, Glasgow, Lanark, Scotland
[2] Univ Strathclyde, Dept Immunol, Glasgow, Lanark, Scotland
关键词
sodium stibogluconate; non-ionic surfactant vesicles; carrier-mediated therapy; dog; pharmacokinetics; tissue antimony concentrations; niosomes;
D O I
10.3109/10611869308996069
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and tissue distribution of antimony after the administration of sodium stibogluconate in a free form or entrapped in vesicles prepared from non-ionic surfactant were studied in the dog. Animals were given either one or two intravenous bolus injection(s) equivalent to 45 mg Sb kg(-1) as free drug or 0.625 or 0.685 mg Sb kg(-1) as vesicular drug. Blood samples were taken at various times after dosing and antimony levels in various tissues were determined at 3 h, 48 h and 6 days after dosing. After free stibogluconate antimony clearance from the blood occurred in a rapid elimination phase with a blood half-life of 0.58 +/- 0.08 h. This rapid elimination phase did not occur after vesicular drug. Both drug preparations gave similar antimony levels in the spleen, liver and femur and humerus bone marrow at all time points assessed even though the vesicular dose was one-seventieth of the free drug dose. After the free drug there was marked urinary excretion of antimony and, as a result, increased kidney loading at the expense of other tissue. Vesicle-mediated drug delivery suppressed renal excretion and a much greater proportion of the antimony dose was recovered from tissue than was obtained after free drug. A hypothesis is presented to account for the differences in tissue antimony concentrations produced by the two formulations.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 25 条
[1]  
ALVING C R, 1986, Parasitology Today, V2, P101, DOI 10.1016/0169-4758(86)90039-6
[2]   IMPROVED THERAPY OF EXPERIMENTAL LEISHMANIASIS BY USE OF A LIPOSOME-ENCAPSULATED ANTIMONIAL DRUG [J].
ALVING, CR ;
STECK, EA ;
HANSON, WL ;
LOIZEAUX, PS ;
CHAPMAN, WL ;
WAITS, VB .
LIFE SCIENCES, 1978, 22 (12) :1021-1026
[3]  
[Anonymous], 1989, MERCK INDEX, P111
[4]   PHARMACOKINETICS OF PENTAVALENT ANTIMONY (PENTOSTAM) IN HAMSTERS [J].
BERMAN, JD ;
GALLALEE, JF ;
GALLALEE, JV .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1988, 39 (01) :41-45
[5]   USE OF PENTOSTAM LIPOSOMES IN CHEMOTHERAPY OF EXPERIMENTAL LEISHMANIASIS [J].
BLACK, CDV ;
WATSON, GJ .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1977, 71 (06) :550-552
[6]   THE THERAPEUTIC EFFECT OF SODIUM STIBOGLUCONATE IN BALB/C MICE INFECTED WITH LEISHMANIA-DONOVANI IS ORGAN-DEPENDENT [J].
CARTER, KC ;
BAILLIE, AJ ;
ALEXANDER, J ;
DOLAN, TF .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1988, 40 (05) :370-373
[7]   VISCERAL LEISHMANIASIS - DRUG CARRIER SYSTEM CHARACTERISTICS AND THE ABILITY TO CLEAR PARASITES FROM THE LIVER, SPLEEN AND BONE-MARROW IN LEISHMANIA-DONOVANI INFECTED BALB/C MICE [J].
CARTER, KC ;
DOLAN, TF ;
ALEXANDER, J ;
BAILLIE, AJ ;
MCCOLGAN, C .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1989, 41 (02) :87-91
[8]  
CHAPMAN WL, 1984, AM J VET RES, V45, P1028
[9]   PHARMACOKINETICS OF ANTIMONY DURING TREATMENT OF VISCERAL LEISHMANIASIS WITH SODIUM STIBOGLUCONATE OR MEGLUMINE ANTIMONIATE [J].
CHULAY, JD ;
FLECKENSTEIN, L ;
SMITH, DH .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1988, 82 (01) :69-72
[10]  
Clark B., 1986, INTRO PHARMACOKINETI